We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

MMF Influence on HCV Viral Evolution After Liver Transplantation

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00170131
First Posted: September 15, 2005
Last Update Posted: May 23, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Hoffmann-La Roche
Information provided by:
Mayo Clinic
  Purpose
Samples from a large clinical trial comparing three immunosuppression regimens, two of which contained MMF, are used to identify the HCV viral quasispecies behaviour after liver transplantation

Condition Phase
HCV Infection Liver Transplantation Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: The Influence MMF on 5UTR HCV Quasispecies Variation: A Potential Factor in the Natural History of Post-OLT x HCV Infection

Resource links provided by NLM:


Further study details as provided by Mayo Clinic:

Enrollment: 17
Study Start Date: September 2002
Study Completion Date: July 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
All patients enrolled into - An Open Randomized, Prospective Multicenter Study to Compare the Efficacy and Safety Among Three Immunosuppressant Treatment Regimens in Patients Receiving a Liver Transplant for End-Stage Liver Disease Caused by Chronic Hepatitis C Infection
Criteria
All patients enrolled into - An Open Randomized, Prospective Multicenter Study to Compare the Efficacy and Safety Among Three Immunosuppressant Treatment Regimens in Patients Receiving a Liver Transplant for End-Stage Liver Disease Caused by Chronic Hepatitis C Infection
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00170131


Locations
United States, Arizona
Mayo Clinic
Scottsdale, Arizona, United States, 85259
Sponsors and Collaborators
Mayo Clinic
Hoffmann-La Roche
Investigators
Principal Investigator: Hugo E. Vargas, M.D. Mayo Clinic
  More Information

ClinicalTrials.gov Identifier: NCT00170131     History of Changes
Other Study ID Numbers: 1801-02
CEL358
First Submitted: September 13, 2005
First Posted: September 15, 2005
Last Update Posted: May 23, 2011
Last Verified: May 2011

Additional relevant MeSH terms:
Infection


To Top